Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Celularity (NASDAQ:CELU): New Jersey Manufacturing Deal with MuseCell Innovations Could Generate Over $300 Million in Orders

By anchoring production domestically, the partnership positions Celularity (NASDAQ:CELU) toSupplyMuseCell-derived material from an established U.S. manufacturing base rather than relying on external or overseas production capacity, a structure that can matter for supply-chain reliability in cell-therapy manufacturing.

Nitish Kishor | 28 August 2026

Adicet Bio (NASDAQ:ACET): FDA Clears IND for ADI-212 in Prostate Cancer

With the IND cleared, Adicet Bio (NASDAQ:ACET) has outlined plans to begin Phase 1 enrollment in the fourth quarter of 2026. As an early-stage, first-in-human study, the initial Phase 1 trial will primarily focus on establishing the safety profile and appropriate dosing of ADI-212, …

Nitish Kishor | 28 August 2026

Iran Warns Countries as Jackson Hole Looms, PayPal Craters, Affirm & Gap Soar, Marvell Falls and Nvidia's Surge Ripples Through Markets: 7 Reads Before Friday's Bell

1. IRAN: Foreign Ministry Warns Against Complicity With US Sanctions as Diplomatic Signals Mix With Contradictory Claims Over Hormuz

Nitish Kishor | 28 August 2026

SNDL (NASDAQ:SNDL) Falls as Soft Retail Demand Weighs on Shares

SNDL (NASDAQ:SNDL), one of Canada's largest cannabis and liquor retailers, fell as soft consumerDemandpressured its core retail businesses—even as a fortress balance sheet, activeBuybacksand a bold expansion into U.S. cannabis continue to define the longer-term story. The tension between near-term softness and long-term optionality …

Nitish Kishor | 28 August 2026

Upwork (NASDAQ:UPWK) Jumps on Record Profitability and AI-Driven Demand

Upwork (NASDAQ:UPWK), the online marketplace connecting businesses with freelancers, jumped as it reported record profitability metrics and surgingDemandfor AI-related work. The move focuses attention on the central tension in Upwork's story: whether artificial intelligence is a threat that automates away freelance work or an …

Nitish Kishor | 28 August 2026

VirTra (NASDAQ:VTSI) Slips as Government Funding Delays Weigh on Revenue

VirTra (NASDAQ:VTSI), a maker of use-of-force and firearmsTrainingsimulators for law enforcement and military customers, slipped as government funding and procurement timing continued to weigh on its revenue. For investors, the question is whether the next catalyst—a release of budget dollars or a rebound in …

Nitish Kishor | 28 August 2026

Waterdrop (NYSE:WDH) Holds Steady Despite Strong Fundamentals

Waterdrop (NYSE:WDH), a Chinese insurance-and-healthcare technology platform, traded roughly flat despite delivering strong revenue growth, consistent profitability andShareholderreturns. Trading at a low valuation with a dividend, the company raises the question of whether it could be ready for its next big move—or whether the …

Nitish Kishor | 28 August 2026

Rekor Systems (NASDAQ:REKR) Ticks Higher Despite a Looming Debt Maturity

Rekor Systems (NASDAQ:REKR), a developer of AI-powered roadway-intelligence technology, edged higher as investors weighed improving operating metrics against a stark going-concern warning and a loomingDebtmaturity. The move poses a high-stakes question: is this an opportunity as theBusinessapproaches profitability, or a signal of more risk …

Nitish Kishor | 28 August 2026

Rail Vision (NASDAQ:RVSN) Drops Even as Revenue Surges from a Tiny Base

Rail Vision (NASDAQ:RVSN), an Israeli developer of AI-powered obstacle-detection systems for railways, dropped even as its revenue surged from a tiny base and its products began gaining commercial traction. For investors, the weakness poses a familiar early-stage-technology question: can the company find a floor …

Nitish Kishor | 28 August 2026

Summit Therapeutics (NASDAQ:SMMT) Surges on Growing Confidence in Ivonescimab

Summit Therapeutics (NASDAQ:SMMT), a biotechnology company developing the closely watched cancer immunotherapy ivonescimab, rose as maturing survival data and an approaching regulatory decision reinforced investor optimism. For a company whose value is tightly bound to a single high-profile drug, the question is whether the …

Nitish Kishor | 28 August 2026
Support

Hi! How can we help you today?

Loading…